Fluorodopa

CHEMBL3547132 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
215.2 g/mol
LogP
-2.0
Phase
4

A radioactive diagnostic agent used in medical imaging to assess dopamine system function in the brain, as well as to detect certain melanoma tumors and evaluate liver conditions. It is administered before a PET scan to help doctors visualize how specific tissues are functioning.

분자량

215.1800 g/mol

LogP

-2.00

TPSA

104.00 Ų

리핀스키 5의 법칙

통과

치료 영역

작용 기전

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

N[C@@H](Cc1cc(O)c(O)cc1F)C(=O)O

InChI

InChI=1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1

Molecular Formula

C9H10FNO4

HBD / HBA

4 / 6

회전 가능 결합

3

무거운 원자

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A radioactive diagnostic agent used in medical imaging to assess dopamine system function in the brain, as well as to detect certain melanoma tumors and evaluate liver conditions. It is administered before a PET scan to help doctors visualize how specific tissues are functioning.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Fluorodopa is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3547132. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 107730. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.